Our Network Imfinzi plus Imjudo demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial Tags: #Oncology #Clinical research #AstraZeneca Longest survival follow-up reported to date for a Phase III trial in this setting
